Log in

NASDAQ:KMDA - Kamada Stock Price, Forecast & News

$5.49
-0.05 (-0.90 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$5.28
Now: $5.49
$5.50
50-Day Range
$4.56
MA: $5.82
$7.13
52-Week Range
$4.40
Now: $5.49
$8.00
Volume34,169 shs
Average Volume136,674 shs
Market Capitalization$244.41 million
P/E Ratio10.17
Dividend YieldN/A
Beta1.33
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, Kamada Ltd. provides Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. Its products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent, which are in Phase II stage; and D1-AAT (IV) for type-1 diabetes, Inhaled AAT for AAT deficiency, and AAT (liquid) for lung preservation and recombinant AAT, which are in early stage development. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion S.p.A. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel.
Read More
Kamada logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.19 million
Cash Flow$0.60 per share
Book Value$3.04 per share

Profitability

Net Income$22.25 million

Miscellaneous

Employees408
Market Cap$244.41 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.


Kamada (NASDAQ:KMDA) Frequently Asked Questions

How has Kamada's stock been impacted by COVID-19 (Coronavirus)?

Kamada's stock was trading at $5.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KMDA shares have increased by 6.6% and is now trading at $5.49. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kamada?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kamada.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Kamada.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Wednesday, February, 12th. The biotechnology company reported $0.13 earnings per share for the quarter, meeting analysts' consensus estimates of $0.13. The biotechnology company had revenue of $32.07 million for the quarter, compared to the consensus estimate of $31.63 million. Kamada had a return on equity of 17.56% and a net margin of 17.50%. View Kamada's earnings history.

What guidance has Kamada issued on next quarter's earnings?

Kamada updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $132-137 million, compared to the consensus revenue estimate of $135.67 million.

What price target have analysts set for KMDA?

2 analysts have issued twelve-month price objectives for Kamada's stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View analysts' price targets for Kamada.

What are Wall Street analysts saying about Kamada stock?

Here are some recent quotes from research analysts about Kamada stock:
  • 1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (2/18/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019)

Has Kamada been receiving favorable news coverage?

Media coverage about KMDA stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kamada earned a news impact score of -4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutKamada.

Are investors shorting Kamada?

Kamada saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 30,000 shares, an increase of 581.8% from the February 27th total of 4,400 shares. Based on an average trading volume of 127,400 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company's stock are short sold. View Kamada's Current Options Chain.

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Micron Technology (MU).

Who are Kamada's key executives?

Kamada's management team includes the following people:
  • Mr. Amir London, Chief Exec. Officer (Age 50)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 49)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
  • Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.11%), Norges Bank (0.90%), Marshall Wace LLP (0.19%), ARK Investment Management LLC (0.17%), UBS Group AG (0.15%) and Jane Street Group LLC (0.13%).

Which institutional investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC.

Which institutional investors are buying Kamada stock?

KMDA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, UBS Group AG, Marshall Wace LLP, Seizert Capital Partners LLC, and Jane Street Group LLC.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.49.

How big of a company is Kamada?

Kamada has a market capitalization of $244.41 million and generates $127.19 million in revenue each year. The biotechnology company earns $22.25 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe. View additional information about Kamada.

What is Kamada's official website?

The official website for Kamada is http://www.kamada.com/.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (NASDAQ KMDA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  500
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel